AU2021332085B2 - Glucosidase inhibitors for the treatment and prevention of pulmonary infections - Google Patents
Glucosidase inhibitors for the treatment and prevention of pulmonary infections Download PDFInfo
- Publication number
- AU2021332085B2 AU2021332085B2 AU2021332085A AU2021332085A AU2021332085B2 AU 2021332085 B2 AU2021332085 B2 AU 2021332085B2 AU 2021332085 A AU2021332085 A AU 2021332085A AU 2021332085 A AU2021332085 A AU 2021332085A AU 2021332085 B2 AU2021332085 B2 AU 2021332085B2
- Authority
- AU
- Australia
- Prior art keywords
- groups
- optionally substituted
- glucosidase inhibitor
- subject
- agis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020903051 | 2020-08-26 | ||
| AU2020903051A AU2020903051A0 (en) | 2020-08-26 | Compounds, compositions and uses thereof | |
| PCT/AU2021/050978 WO2022040741A1 (en) | 2020-08-26 | 2021-08-25 | Glucosidase inhibitors for the treatment and prevention of pulmonary infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021332085A1 AU2021332085A1 (en) | 2022-05-19 |
| AU2021332085B2 true AU2021332085B2 (en) | 2022-12-08 |
Family
ID=80352192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021332085A Active AU2021332085B2 (en) | 2020-08-26 | 2021-08-25 | Glucosidase inhibitors for the treatment and prevention of pulmonary infections |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240016786A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4203954A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023540259A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116419754A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021332085B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022040741A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100027464A1 (it) * | 2021-10-26 | 2023-04-26 | Univ Degli Studi Di Camerino | Composizione comprendente iminozuccheri e/o anisodamina per il trattamento di infezioni virali |
| US12569473B2 (en) * | 2022-07-05 | 2026-03-10 | 60 Degrees Pharmaceuticals, Inc. | Methods to treat respiratory infection utilizing castanospermine analogs |
| CN119841765B (zh) * | 2025-01-09 | 2025-10-10 | 中南大学 | Dnj衍生物、药物组合物及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022975A1 (en) * | 1994-02-25 | 1995-08-31 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
| WO2017192599A1 (en) * | 2016-05-02 | 2017-11-09 | Florida State University Research Foundation, Inc. | Treatment of zika virus infections using alpha-glucosidase inhibitors |
| WO2020185675A1 (en) * | 2019-03-08 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for modulating viral infections by regulating glucosylceramides |
| WO2021168483A2 (en) * | 2020-02-21 | 2021-08-26 | Florida State University Research Foundation, Inc. | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors |
| AU2021202066A1 (en) * | 2020-04-03 | 2021-10-21 | Shenzhen Qianhai Nobel Laureates Technology Transfer Co., Ltd. | Use of iminosugar compound in preparation of anti-sars-cov-2 virus drug |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116643D0 (en) * | 2001-07-09 | 2001-08-29 | Virogen Ltd | Antiviral compounds |
| FR2861991B1 (fr) * | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| WO2011095772A2 (en) * | 2010-02-04 | 2011-08-11 | Summit Corporation Plc | Novel iminosugar therapeutics |
| RS58456B1 (sr) * | 2011-08-01 | 2019-04-30 | Univ Monash | Postupak i formulacije za inhalaciju |
| US10980756B1 (en) * | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| US20230270826A1 (en) * | 2020-07-30 | 2023-08-31 | Delta 4 Gmbh | Antiviral use of liraglutide and gefitinib |
-
2021
- 2021-08-25 CN CN202180072511.2A patent/CN116419754A/zh active Pending
- 2021-08-25 AU AU2021332085A patent/AU2021332085B2/en active Active
- 2021-08-25 JP JP2023513877A patent/JP2023540259A/ja active Pending
- 2021-08-25 US US18/022,840 patent/US20240016786A1/en active Pending
- 2021-08-25 WO PCT/AU2021/050978 patent/WO2022040741A1/en not_active Ceased
- 2021-08-25 EP EP21859409.1A patent/EP4203954A4/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022975A1 (en) * | 1994-02-25 | 1995-08-31 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
| WO2017192599A1 (en) * | 2016-05-02 | 2017-11-09 | Florida State University Research Foundation, Inc. | Treatment of zika virus infections using alpha-glucosidase inhibitors |
| WO2020185675A1 (en) * | 2019-03-08 | 2020-09-17 | University Of Virginia Patent Foundation | Compositions and methods for modulating viral infections by regulating glucosylceramides |
| WO2021168483A2 (en) * | 2020-02-21 | 2021-08-26 | Florida State University Research Foundation, Inc. | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors |
| AU2021202066A1 (en) * | 2020-04-03 | 2021-10-21 | Shenzhen Qianhai Nobel Laureates Technology Transfer Co., Ltd. | Use of iminosugar compound in preparation of anti-sars-cov-2 virus drug |
Non-Patent Citations (8)
| Title |
|---|
| FUKUSHI, M. et al. Journal of Virology (2012) vol. 86, no. 21, pages 11745-11753 * |
| HOLWERDA, M. et al. "Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2" bioRxiv (2020) 1-25, Published 17 May 2020 * |
| HUSSAIN, S. et al. Journal of Antimicrobial Chemotherapy (2015) vol. 70, no. 1, pages 136-152 * |
| RAJASEKHARAN, S. et al. "Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2" bioRxiv (2020) 1-17, published 18 May 2020 * |
| TANAKA, Y. et al. Antiviral Research (2006) vol. 72, no. 1, pages 1-9 * |
| WARFIELD, K. L. et al. Journal of Medicinal Chemistry (2020) vol. 63, pages 4205-4214 (published 31 March 2020) * |
| WARFIELD, K. L. et al. Viruses (2016) vol. 8, no. 3, 71, 9 pages * |
| ZHAO, X. et al. Antimicrobial Agents and Chemotherapy (January 2015) vol. 59, no. 1, pages 206-216 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022040741A1 (en) | 2022-03-03 |
| AU2021332085A1 (en) | 2022-05-19 |
| US20240016786A1 (en) | 2024-01-18 |
| CN116419754A (zh) | 2023-07-11 |
| JP2023540259A (ja) | 2023-09-22 |
| EP4203954A4 (en) | 2025-01-01 |
| EP4203954A1 (en) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12396986B2 (en) | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | |
| JP2024028720A (ja) | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 | |
| JP6021117B2 (ja) | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 | |
| JP2020073494A (ja) | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 | |
| US20240016786A1 (en) | Glucosidase inhibitors for the treatment and prevention of pulmonary infections | |
| JP2014525471A (ja) | 咳および咳発作の治療 | |
| TW200938232A (en) | Novel dosage and formulation | |
| KR20150018526A (ko) | 아베디테롤의 신규한 투약 형태 및 제형 | |
| JP2023171770A (ja) | クロファジミンの吸入可能な組成物およびその使用方法 | |
| CN117615765A (zh) | 用ALK-5(TGFβR1)抑制剂治疗肺部疾病的方法 | |
| EP4151211A1 (en) | Novel inhalant | |
| TW201031409A (en) | Novel methods | |
| CN103561731A (zh) | 包含芜地溴铵的干粉吸入器组合物 | |
| US20220378727A1 (en) | Dry powder formulations of tamibarotene for pulmonary and intranasal delivery | |
| US20240041805A1 (en) | Pharmaceutical compositions of niclosamide and a protein | |
| HK40096612A (en) | Glucosidase inhibitors for the treatment and prevention of pulmonary infections | |
| US20230270709A1 (en) | Antiviral pharmaceutical composition for topical administration | |
| TR201407010A2 (tr) | Vilanterol formülasyonları. | |
| US20240299379A1 (en) | Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases | |
| WO2005044233A1 (en) | Formulations of n-oxide prodrugs of local anesthetics for the treatment of pulmonary inflammation associated with asthma, brochitis, and copd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |